FDA Adverse Event Injury Summary report: N

TC3 RP TIBIAL INSERT S5,20.0

MDR report key: 3810266 · Received May 14, 2014

Report

Report Number
1818910-2014-18776
Event Type
Injury
Date Received
May 14, 2014
Date of Event
April 21, 2014
Report Date
April 21, 2014
Manufacturer
DEPUY-RAYNHAM,A DIV. OF DEPUY ORTHOPAEDICS 1219655
Product Code
NJL
PMA / PMN Number
PP830055
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
DE, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

THE DEVICE ASSOCIATED WITH THIS REPORT WAS NOT RETURNED. A COMPLAINT DATABASE SEARCH FINDS NO OTHER REPORTED INCIDENTS AGAINST THE PROVIDED PRODUCT AND LOT COMBINATION. REQUESTS FOR ADDITIONAL INVESTIGATIONAL INPUTS WERE MADE IN ACCORDANCE WITH WI-7915 APPENDIX A. NO ADDITIONAL INFORMATION WAS OBTAINED. THE INVESTIGATION COULD NOT VERIFY OR IDENTIFY ANY PRODUCT CONTRIBUTION TO THE REPORTED EVENT WITH THE INFORMATION PROVIDED. BASED ON THE INABILITY TO IDENTIFY ROOT CAUSE, THE NEED FOR CORRECTIVE ACTION WAS NOT INDICATED. DEPUY CONSIDERS THE INVESTIGATION CLOSED AT THIS TIME. SHOULD ADDITIONAL INFORMATION BE RECEIVED, THE INFORMATION WILL BE REVIEWED AND THE INVESTIGATION WILL BE RE-OPENED AS NECESSARY.

Additional Manufacturer Narrative · 1

DEPUY STILL CONSIDERS THE INVESTIGATION CLOSED. SHOULD ADDITIONAL INFORMATION BE RECEIVED, THE INFORMATION WILL BE REVIEWED AND THE INVESTIGATION WILL BE REOPENED AS NECESSARY.

Additional Manufacturer Narrative · 1

IF INFORMATION IS OBTAINED THAT WAS NOT AVAILABLE FOR THE INITIAL MEDWATCH, A FOLLOW-UP MEDWATCH WILL BE FILED AS APPROPRIATE. THIS COMPLAINT IS STILL UNDER INVESTIGATION. DEPUY WILL NOTIFY THE FDA OF THE RESULTS OF THIS INVESTIGATION ONCE IT HAS BEEN COMPLETED.

Description of Event or Problem · 1

PATIENT WAS REVISED DUE TO SUSPECTED INFECTION.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
288453 TC3 RP TIBIAL INSERT S5,20.0 KNEE TIBIAL INSERT NJL DEPUY-RAYNHAM,A DIV. OF DEPUY ORTHOPAEDICS 1219655 D2REC4000

Patients

Seq Age Sex Outcome Treatment
1 82 YR Required Intervention